Clinical trial
A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)
NCT06684873 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)
- Lead sponsor
- Sun Yat-sen University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 2, 2024
- Completion date
- December 1, 2027
- Enrollment
- 55 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
brain metastasases, nsclc